Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report)’s share price was up 3.5% during mid-day trading on Tuesday . The stock traded as high as $3.40 and last traded at $3.25. Approximately 66,286 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 71,822 shares. The stock had previously closed at $3.14.
Cyclerion Therapeutics Trading Up 3.5 %
The business’s 50 day moving average is $2.88 and its 200 day moving average is $2.86.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Further Reading
- Five stocks we like better than Cyclerion Therapeutics
- What to Know About Investing in Penny Stocks
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Insider Buying Explained: What Investors Need to Know
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
